Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Positive Non-small Cell Lung Cancer”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)Looking for participantsNCT07169552
What this trial is testing

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

Who this might be right for
NSCLC
HC Biopharma Inc. 50
Large-scale testing (Phase 3)UnknownNCT05042375
What this trial is testing

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 450
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Not applicableUnknownNCT04322591
What this trial is testing

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Large-scale testing (Phase 3)Active Not RecruitingNCT05499390
What this trial is testing

AK112 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-small-cell Lung Cancer
Akeso 398
Testing effectiveness (Phase 2)Active Not RecruitingNCT04392505
What this trial is testing

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Who this might be right for
CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer Stage III+2 more
Oslo University Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06980272
What this trial is testing

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 420
Large-scale testing (Phase 3)Looking for participantsNCT07144280
What this trial is testing

Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma
Pfizer 680
Large-scale testing (Phase 3)Study completedNCT03850444
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 262
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Not applicableStudy completedNCT03911219
What this trial is testing

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Who this might be right for
Stage IV Non-small Cell Lung CancerExtensive-stage Small Cell Lung CancerAdvanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
iOMEDICO AG 154
Testing effectiveness (Phase 2)Ended earlyNCT04515979
What this trial is testing

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedPacto, Inc. 11
Testing effectiveness (Phase 2)Looking for participantsNCT05751798
What this trial is testing

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Solid Advanced TumorLymphomaNSCLC (Non-small Cell Lung Cancer)
OSE Immunotherapeutics 41
Post-approval studies (Phase 4)Study completedNCT03715205
What this trial is testing

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

Who this might be right for
Carcinoma, Non-Small-Cell LungMelanoma
Merck Sharp & Dohme LLC 150
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Not applicableStudy completedNCT05321212
What this trial is testing

Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

Who this might be right for
Carcinoma, Non-Small-Cell LungImmunotherapy
University Hospital, Brest 108
Testing effectiveness (Phase 2)Active Not RecruitingNCT04622007
What this trial is testing

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Who this might be right for
Non-small Cell Lung Cancer
Effector Therapeutics 68
Testing effectiveness (Phase 2)Study completedNCT04165083
What this trial is testing

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955290
What this trial is testing

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Who this might be right for
Advanced Head and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell Carcinoma+13 more
Roswell Park Cancer Institute 51
Load More Results